Overview

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2016-08-17

Target enrollment:

Participant gender:

Summary

The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

GlaxoSmithKline

Treatments:

Adalimumab
Antibodies, Monoclonal